Antihypertensive activity of 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline (MJ 10459-2) and catecholamine reduction

Res Commun Chem Pathol Pharmacol. 1975 Sep;12(1):155-62.

Abstract

Antihypertensive activity of 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline hydrobromide (MJ 10459-2) was assessed in conscious, spontaneously hypertensive and stress-induced hypertensive rats via indirect determination of systolic blood pressure. Subcutaneous administration of 1-4 mg/kg resulted in lowering of blood pressure that was dose related. No reductions in the content of norepinephrine, dopamine, serotonin or 5-hydroxyindoleacetic acid were noted in the cerebrum, cerebellum, midbrain or medulla/pons area of brain after 1 and 4 mg/kg of MJ 10459-2. Cardiac tissue norepinephrine was reduced to 4-6% of control values after subcutaneous doses of 0.2-20 mg/kg of MJ 10459-2 in hypertensive and normotensive rats. These data suggest that at least part of the blood pressure lowering effects of MJ 10459-2 may involve reduction of peripheral noradrenergic stores.

MeSH terms

  • Animals
  • Antihypertensive Agents* / therapeutic use
  • Blood Pressure / drug effects
  • Brain / metabolism
  • Catecholamines / metabolism*
  • Chlorobenzenes / pharmacology
  • Chlorobenzenes / therapeutic use
  • Depression, Chemical
  • Dopamine / metabolism
  • Hydroxyindoleacetic Acid / metabolism
  • Hypertension / drug therapy
  • Hypertension / etiology
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Male
  • Myocardium / metabolism
  • Norepinephrine / metabolism
  • Rats
  • Serotonin / metabolism
  • Stress, Physiological / complications
  • Time Factors

Substances

  • Antihypertensive Agents
  • Catecholamines
  • Chlorobenzenes
  • Imidazoles
  • Serotonin
  • Hydroxyindoleacetic Acid
  • Dopamine
  • Norepinephrine